RxDoctor Payments Data

Ram Penmetsa, MD

Cardiovascular Disease · Gainesville, GANPI 1427084102

Payments from drug & device makers

$2,084in general payments, 2019–2025

Across 85 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$352
  • Novartis$345
  • Amgen$304
  • Johnson & Johnson$223
  • Abbott$154
  • E.r. Squibb & Sons, L.L.C.$149
  • plus $558 from 11 others

What the payments were for

  • Food & beverage$2,084100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,084 in reported general payments places this provider in the 45th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$58,365
Medicare patients
518
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$60,793
XareltoRivaroxaban18$13,250
EntrestoSacubitril/Valsartan17$12,340
Metoprolol Succinate53$635
Atorvastatin Calcium52$192
Rosuvastatin Calcium17$187
ClopidogrelClopidogrel Bisulfate16$183
Isosorbide Mononitrate ErIsosorbide Mononitrate23$178
Metoprolol Tartrate51$170
Carvedilol39$161
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$126
Furosemide42$116
Nitroglycerin11$98
Hydralazine Hcl15$90
Amlodipine Besylate37$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$60,79381 claims
Johnson & JohnsonXarelto$223$13,25018 claims
NovartisEntresto$345$12,34017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →